Vaccines for opioid dependence may provide a treatment that would reduce or slow the distribution of the drug to brain, thus reducing the drug's reinforcing effects. We tested whether a conjugate vaccine against morphine (keyhole limpet hemocyanin-6-succinylmorphine; KLH-6-SM) administered to rats would produce antibodies and show specificity for morphine or other heroin metabolites. The functional effects of the vaccine were tested with antinociceptive and conditioned place preference (CPP) tests. Rats were either vaccinated with KLH-6-SM and received two boosts 3 and 16 weeks later or served as controls and received KLH alone. Anti-morphine antibodies were produced in vaccinated rats; levels increased and were sustained at moderate levels through 24 weeks. Antibody binding was inhibited by free morphine and other heroin metabolites as demonstrated by competitive inhibition ELISA. Vaccinated rats showed reduced morphine CPP, tested during weeks 4 to 6, and decreased antinociceptive responses to morphine, tested at week 7. Brain morphine levels, assessed using gas-chromatography coupled to mass spectrometry (GC-MS) on samples obtained at 26 weeks, were significantly lower in vaccinated rats. This suggests that morphine entry into the brain was reduced or slowed. These results provide support for KLH-6-SM as a candidate vaccine for opioid dependence.
Introduction
Opioid dependence is a serious health problem in the United States and world-wide (UNODC, 2010) . Relapse rates remain high even though there are approved pharmacological treatments for this disorder (Veilleux et al., 2010) . Medications currently approved to treat opioid dependence include methadone, buprenorphine, and naltrexone (Maxwell and Shinderman, 2002; Stotts et al., 2009 ). These agents act at opioid receptors as an agonist, a partial agonist, or an antagonist, respectively. While each of these treatments shows some therapeutic success, there are numerous limitations to their use, including high cost, limited availability, problems with compliance, and, in the case of the agonists, diversion (Kahan et al., 2001; Kreek et al., 2010; Stotts et al., 2009 ). An alternative strategy to developing a treatment for opioid dependence is an anti-opioid vaccine (Shen et al., 2012) .
The approach for the development of drug addiction vaccines differs from the approach used in the development of the other medications. Whereas the opioidergic treatment agents were designed to target opioidergic effector systems in the brain through pharmacodynamic mechanisms, vaccines act as "pharmocokinetic" antagonists. Upon administration, the vaccine stimulates the production of drugspecific antibodies that can bind to the drug in the circulating blood and extracellular fluid when the drug is ingested. This action should reduce or slow the distribution of the drug to brain and theoretically attenuate the drug's reinforcing or addictive effects. Support for the vaccine approach has been shown by the promising results obtained in clinical trials for vaccines designed for the treatments of cocaine and nicotine addiction (Haney et al., 2010; Hatsukami et al., 2011; Martell et al., 2009 ).
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Abbreviations: CPP, conditioned place preference; KLH, keyhole limpet hemocyanin; BSA, bovine serum albumin; 6-SM, 6-succinylmorphine; KLH-6-SM, keyhole limpet hemocyanin-6-succinylmorphine; alum, aluminum hydroxide gel; 6-AM, 6-acetyl morphine; 3-GM, morphine-3-glucuronide; 6-GM, morphine-6-glucuronide; EDC, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride; sulfo-NHS, N-hydroxysulfosuccinimide; ELISA, enzyme-linked immunosorbent assay; GC-MS, gas-chromatography coupled to mass spectrometry; IC50, 50% inhibition of maximum binding; MPE, maximal possible effect.
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